NASDAQ:SPHS - Sophiris Bio Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.08 +0.02 (+1.89 %) (As of 01/17/2019 03:40 AM ET)Previous Close$1.06Today's Range$1.05 - $1.0952-Week Range$0.75 - $4.05Volume134,900 shsAverage Volume203,664 shsMarket Capitalization$33.12 millionP/E Ratio-2.70Dividend YieldN/ABeta2.7 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California. Receive SPHS News and Ratings via Email Sign-up to receive the latest news and ratings for SPHS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPHS Previous Symbol CUSIPN/A Webwww.sophirisbio.com Phone858-777-1760Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16Price-To-Earnings Trailing P/E Ratio-2.70 Forward P/E Ratio-2.16 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book4.32Profitability EPS (Most Recent Fiscal Year)($0.40) Net Income$-8,620,000.00 Net MarginsN/A Return on Equity-839.01% Return on Assets-68.03%Miscellaneous Employees6 Outstanding Shares30,110,000Market Cap$33.12 million OptionableOptionable Sophiris Bio (NASDAQ:SPHS) Frequently Asked Questions What is Sophiris Bio's stock symbol? Sophiris Bio trades on the NASDAQ under the ticker symbol "SPHS." How were Sophiris Bio's earnings last quarter? Sophiris Bio Inc (NASDAQ:SPHS) announced its earnings results on Tuesday, November, 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. View Sophiris Bio's Earnings History. When is Sophiris Bio's next earnings date? Sophiris Bio is scheduled to release their next quarterly earnings announcement on Wednesday, March 20th 2019. View Earnings Estimates for Sophiris Bio. What price target have analysts set for SPHS? 2 brokers have issued twelve-month target prices for Sophiris Bio's shares. Their predictions range from $6.00 to $10.00. On average, they anticipate Sophiris Bio's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 640.7% from the stock's current price. View Analyst Price Targets for Sophiris Bio. What is the consensus analysts' recommendation for Sophiris Bio? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sophiris Bio in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sophiris Bio. What are Wall Street analysts saying about Sophiris Bio stock? Here are some recent quotes from research analysts about Sophiris Bio stock: 1. Maxim Group analysts commented, "Sophiris’ phase 2B study of topsalysin in localized prostate cancer is approaching its next key data point, effects of a second administration, expected in the next few weeks." (12/6/2018) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $10 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Sophiris Bio Inc." (9/13/2018) Has Sophiris Bio been receiving favorable news coverage? Media stories about SPHS stock have been trending positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sophiris Bio earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. Who are some of Sophiris Bio's key competitors? Some companies that are related to Sophiris Bio include Imprimis Pharmaceuticals (IMMY), Axovant Sciences (AXON), Northwest Biotherapeutics (NWBO), BELLUS Health (BLUSF), Cue Biopharma (CUE), Processa Pharmaceuticals (PCSA), Proteostasis Therapeutics (PTI), Corvus Pharmaceuticals (CRVS), Chembio Diagnostics (CEMI), Adamis Pharmaceuticals (ADMP), Menlo Therapeutics (MNLO), XOMA (XOMA), Avadel Pharmaceuticals (AVDL), Millendo Therapeutics (MLND) and Sol Gel Technologies (SLGL). Who are Sophiris Bio's key executives? Sophiris Bio's management team includes the folowing people: Dr. Lars G. Ekman M.D., Ph.D., Exec. Chairman (Age 68)Mr. Randall E. Woods, CEO, Pres & Director (Age 66)Mr. Peter T. Slover, Chief Financial Officer (Age 43)Dr. Allison J. Hulme, COO, Head of R&D and Director (Age 55)Dr. Samuel R. Denmeade, Chief Scientific Officer & Member of the Scientific Advisory Board Who are Sophiris Bio's major shareholders? Sophiris Bio's stock is owned by many different of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.12%). View Institutional Ownership Trends for Sophiris Bio. Which institutional investors are buying Sophiris Bio stock? SPHS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Sophiris Bio. How do I buy shares of Sophiris Bio? Shares of SPHS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sophiris Bio's stock price today? One share of SPHS stock can currently be purchased for approximately $1.08. How big of a company is Sophiris Bio? Sophiris Bio has a market capitalization of $33.12 million. The biopharmaceutical company earns $-8,620,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Sophiris Bio employs 6 workers across the globe. What is Sophiris Bio's official website? The official website for Sophiris Bio is http://www.sophirisbio.com. How can I contact Sophiris Bio? Sophiris Bio's mailing address is 1258 PROSPECT STREET, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-777-1760 or via email at [email protected] MarketBeat Community Rating for Sophiris Bio (NASDAQ SPHS)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 223 (Vote Outperform)Underperform Votes: 111 (Vote Underperform)Total Votes: 334MarketBeat's community ratings are surveys of what our community members think about Sophiris Bio and other stocks. Vote "Outperform" if you believe SPHS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPHS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: Why do corrections happen?